ReviewInternational journal of retina and vitreous2024
AI-based support for optical coherence tomography in age-related macular degeneration.
Review in International journal of retina and vitreous, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 20 citations in OpenAlex.
- Real-world evaluation of an OCT-based AI decision-support system for neovascular AMD activity triage in teleophthalmology.Frontiers in ophthalmology · 2026Article
- Artificial intelligence in ophthalmology clinical trials: a narrative review.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Review
- Geographic Atrophy Progression in Clinical Practice Before and After Pegcetacoplan Treatment.Vision (Basel, Switzerland) · 2025Article
- Early Outcome Analysis of Intravitreal Aflibercept 8 mg Treatment in Naïve Patients with Neovascular Age-Related Macular Degeneration Using Artificial Intelligence.Ophthalmology and therapy · 2025Article
- Automated fluid monitoring to optimize the follow-up of neovascular age-related macular degeneration patients in the Brazilian population.International journal of retina and vitreous · 2025Article
- Imaging of Geographic Atrophy: A Practical Approach.Ophthalmology and therapy · 2025Article
- Enhancing Ophthalmic Diagnosis and Treatment with Artificial Intelligence.Medicina (Kaunas, Lithuania) · 2025Review
- Photoreceptor assessment in age-related macular degeneration.Eye (London, England) · 2025Review
- Artificial Intelligence Applications in Ophthalmology.JMA journal · 2025Review
- Faricimab efficacy in type 1 macular neovascularization: AI-assisted quantification of pigment epithelium detachment (PED) volume reduction over 12 months in Naïve and switch eyes.International journal of retina and vitreous · 2025Article
- Organisational impact and patient management models for biomarker integration in multiple sclerosis care in Italy: the 0Tolerance project.BMJ neurology open · 2025Article
- Evaluation of retinal structure changes with AI-based OCT image segmentation for sodium iodate induced retinal degeneration.Frontiers in cellular neuroscience · 2025Article
- Importance of OCT-derived biomarkers for the recurrence of central serous chorioretinopathy using statistics and predictive modelling.Scientific reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Artificial intelligence (AI) has emerged as a transformative technology across various fields, and its applications in the medical domain, particularly in ophthalmology, has gained significant attention. The vast amount of high-resolution image data, such as optical coherence tomography (OCT) images, has been a driving force behind AI growth in this field. Age-related macular degeneration (AMD) is one of the leading causes for blindness in the world, affecting approximately 196 million people worldwide in 2020. Multimodal imaging has been for a long time the gold standard for diagnosing patients with AMD, however, currently treatment and follow-up in routine disease management are mainly driven by OCT imaging. AI-based algorithms have by their precision, reproducibility and speed, the potential to reliably quantify biomarkers, predict disease progression and assist treatment decisions in clinical routine as well as academic studies. This review paper aims to provide a summary of the current state of AI in AMD, focusing on its applications, challenges, and prospects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.